Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
|Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Patent applications|
|Patent application number||Title||Published|
|20130210969||FEEDBACK ACTIVE COATINGS WITH SENSITIVE CONTAINERS BASED ON NANO-, MICRO-, MINI-, AND MACROEMULSIONS OF DIRECT OR REVERSED TYPE - Nano- or microsized containers include either a water immiscible or sparingly miscible core dispersible in aqueous dispersion medium or a water miscible core dispersible in non-aqueous dispersion medium and a core-soluble active agent selected from the group consisting of corrosion inhibitors, catalysts, accelerators of catalysts, adhesives, sealants, polymerizable compounds (monomers), surfactants, lubricants, antifouling agents, water repelling materials and their mixtures, and a stimulus-sensitive polymer/polyelectrolyte shell that encapsulates the core-soluble active agent and releases the encapsulated agent in response to an external stimulus selected from the group consisting of humidity, ionic strength, pH, temperature, mechanical stress, constant and alternating magnetic or electromagnetic fields, corrosion products, electric current, and electrochemical potential.||08-15-2013|
|20130145957||CORROSION INHIBITING PIGMENTS AND METHODS FOR PREPARING THE SAME - A pigment includes reservoirs of encapsulated corrosion inhibitors and/or biocides for active corrosion and/or antifouling protection of metallic and polymeric products and structures, wherein the reservoirs have average dimensions of 10-50000 nm and comprise a porous surface/interface, a porous or empty interior and stimuli-sensitive stoppers that release an encapsulated inhibitor or biocide outside the reservoir upon action of a stimulus selected from the group consisting of an external electromagnetic field, changes in local pH, ionic strength and ambient temperature, wherein the stimuli-sensitive stoppers result from a chemical or physical interaction between encapsulated corrosion inhibitor and/or biocide or encapsulated solvent/dispersing agent and an additional external compound and prevent release of an encapsulated inhibitor or biocide towards an exterior of the reservoir in the absence of the stimulus.||06-13-2013|
|20120202068||PROCESS FOR DEPOSITION OF THIN LAYERS OF METAL OXIDES - The invention relates to a process for the deposition of a metal oxide, such as titanium dioxide, as a thin layer on a substrate, by using particular biopolymers, in particular, a hydrophobin. The process for the deposition of a metal oxide on a substrate (S) comprises the steps of depositing a protein layer (H) comprising at least one hydrophobin on the substrate and the deposition of a metal oxide layer (M) on the protein layer (H) by precipitation from an aqueous solution of a metal salt.||08-09-2012|
|20110182920||IDENTIFICATION OF A NOVEL CYSTEINE-RICH CELL PENETRATING PEPTIDE - The present invention relates to a nucleic acid molecule encoding a peptide capable of being internalized into a cell, wherein said nucleic acid molecule consists of (a) a nucleic acid molecule encoding a peptide having the amino acid sequence of SEQ ID NO: 2; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO: 1, wherein T is U if the nucleic acid molecule is RNA; or (d) a nucleic acid molecule encoding a peptide having at least 80% sequence identity with that of SEQ ID NO: 2, wherein at least at two positions selected from the group consisting of positions 1, 7 and 8 of SEQ ID NO: 2 a cysteine is present and wherein at least at four positions selected from the groups consisting of position 2, 4, 6, 9 or 10 of SEQ ID NO: 2 an arginine or a lysine is present. The present invention also relates to a peptide encoded by the nucleic acid of the invention, a fusion molecule comprising the peptide of the invention and a composition comprising the peptide or the fusion molecule of the invention. Furthermore, the present invention relates to a method of detecting the internalization behaviour of a fusion molecule of the invention, the composition of the invention for treating and/or preventing a condition selected from cancer, enzyme deficiency diseases, infarcts, cerebral ischemia, diabetes, inflammatory diseases, infections such as bacterial, viral or fungal infections, autoimmune diseases such as systemic lupus erythematodes (SLE) or rheumatoid arthritis, diseases with amyloid-like fibrils such as Alzheimer's disease (AD) and Parkinson's disease (PD) or certain forms of myopathy.||07-28-2011|
|20110165564||SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES - A method for detecting sequence specific methylation in a biomolecule, comprising: (a) contacting the biomolecule with an S-adenosyl-||07-07-2011|
|20110155248||HIGH PERFORMANCE SOLUTION PROCESSABLE SEMINCONDUCTOR BASED ON DITHIENO [2,3-D:2',3'-D']BENZO[1,2-B:4,5-B'] DITHIOPHENE - Dithienobenzodithiophenes of general formula (I) in which R||06-30-2011|
|20110040766||Methods for searching with semantic similarity scores in one or more ontologies - A method assigns importance ranks to documents within repositories or databases, such as any database of documents such as books or other printed material, electronic documentation, and pages within the world-wide web. The method uses a corpus of indexed documents that has been annotated to the terms of one or more ontologies in order to assign a semantic similarity score to queries based on terms taken from the ontologies. A statistical model is used to test the significance of matches between query terms and documents or categories. The method results in an acceleration of over 10,000-fold for realistic queries and ontologies, and makes it practicable to calculate P-values dynamically or to keep database annotations and the related P-value distributions up to date by frequent recalculation.||02-17-2011|
|20100143991||METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOLS USING AN AZOARCUS SP. EBN1 DEHYDROGENASE - A method for producing optically active alcohols of formula (Ia) or (Ib), wherein R||06-10-2010|
|20100142054||Wavelength or polarization sensitive optical assembly and use thereof - In an optical assembly having a light source which provides two optically different light components with essentially planar wavefronts on an optical axis, wherein the light components differ at least in their wavelength; in the case of an objective lens which projects the two optically different light components into a projection space; and in the case of an optical component which is arranged on the optical axis and has an plane through which the wavefronts of the two light components pass and in which at least two different areas of the optical component with different dispersion behaviors n(λ) abut against one another in the lateral direction with respect to the optical axis; the optical component causes phase shifts of the wavefronts of the two light components, wherein the phase shift of the wavefronts of the one light component differs by at least one quarter of the wavelength of that light component between the two different areas, and wherein the phase shift of the wavefronts of the other light component does not differ between the two different areas, such that an intensity distribution of the one light component in the projection space by interference with itself differs from an intensity distribution of the other light component in the projection space.||06-10-2010|
|20090321627||METHOD AND SYSTEM FOR HIGH THROUGHPUT MASS ANALYSIS - The invention relates to a test method, especially for mass spectroscopy of biomolecules, including the following steps: one or several samples (||12-31-2009|
|20090186773||Methods For Predicting The Response Of Multiple Sclerosis Patients To Interferon Theraphy And Diagnosing Multiple Sclerosis - The present invention relates to a method of diagnosing a predisposition of a multiple sclerosis (MS) patient for responsiveness to a treatment of MS by administration of interferon-α (IFN-α) and/or interferon-β (IFN-β) and means to perform the method. Furthermore, the invention relates to a method of diagnosing a predisposition of a patient for developing multiple sclerosis (MS) and corresponding means.||07-23-2009|
Patent applications by Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.